Current and Potential Therapeutic Strategies for Heart Failure

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (30 March 2017) | Viewed by 5513

Special Issue Editor

Department of Cardiology, Ninewells Hospital and Medical School, University of Dundee, Dundee, Tayside, DD1 9SY, UK
Interests: cardiovascular therapeutics; translational medicine; heart failure; cardio-metabolic disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite significant advances in pharmacotherapy and therapy, heart failure remains a major cause of mortality and morbidity, and is a growing healthcare burden worldwide. However, there has been a growing understanding of the underlying disease mechanisms of heart failure, although there remain gaps in the knowledge, particularly with respect to acute decompensated heart failure, heart failure with preserved ejection fraction, and in the management of prevalent comorbidities that contribute to its pathophysiology, such as diabetes and anaemia. This Special Issue will focus on recent research and developments in these areas.

Prof. Dr. Chim C. Lang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

498 KiB  
Review
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure
by Abbey Steggall, Ify R. Mordi and Chim C. Lang
Diseases 2017, 5(2), 14; https://doi.org/10.3390/diseases5020014 - 10 May 2017
Cited by 29 | Viewed by 5154
Abstract
Despite significant improvements in morbidity and mortality with current evidence-based pharmaceutical-based treatment of heart failure (HF) over the previous decades, the burden of HF remains high. An alternative approach is currently being developed, which targets myocardial energy efficiency and the dysfunction of the [...] Read more.
Despite significant improvements in morbidity and mortality with current evidence-based pharmaceutical-based treatment of heart failure (HF) over the previous decades, the burden of HF remains high. An alternative approach is currently being developed, which targets myocardial energy efficiency and the dysfunction of the cardiac mitochondria. Emerging evidence suggests that the insufficient availability of ATP to the failing myocardium can be attributed to abnormalities in the myocardial utilisation of its substrates rather than an overall lack of substrate availability. Therefore, the development of potential metabolic therapeutics has commenced including trimetazidine, ranolazine and perhexiline, as well as specific mitochondrial-targeting pharmaceuticals, such as elamipretide. Large randomised controlled trials are required to confirm the role of metabolic-modulating drugs in the treatment of heart failure, but early studies have been promising in their possible efficacy for the management of heart failure in the future. Full article
(This article belongs to the Special Issue Current and Potential Therapeutic Strategies for Heart Failure)
Show Figures

Figure 1

Back to TopTop